Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications

Vaccine

Volumn 34, Issue 45, 2016, Pages 5442-5448

  Sparrow, Erin ^a,b   Friede, Martin ^a   Sheikh, Mohamud ^b   Torvaldsen, Siranda ^b,c   Newall, Anthony T ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Immunization; Influenza; Monoclonal antibody; Pandemic; Prophylaxis; Vaccine

Indexed keywords

CR 8020; DIRIDAVUMAB; FGI 101 1A 6; INFLUENZA VACCINE; MEDI 8852; MHAA 4549A; MONOCLONAL ANTIBODY; NAVIVUMAB; RECOMBINANT ANTIBODY; TCN 032; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIS 410; IMMUNOLOGIC FACTOR; NEUTRALIZING ANTIBODY;

COST EFFECTIVENESS ANALYSIS; DRUG USE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LICENSING; META ANALYSIS; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PUBLIC HEALTH; REVIEW; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PANDEMIC; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC FACTORS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; PRE-EXPOSURE PROPHYLAXIS;

EID: 84992559547     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.057     Document Type: Review

References (34)

1. [1] The World Health Organization Website. Pandemic influenza vaccine manufacturing process and timeline. < http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/>.
2. [2] Kelso, J.K., Halder, N., Milne, G.J., Vaccination strategies for future influenza pandemics: a severity-based cost effectiveness analysis. BMC Infect Dis, 13, 2013, 81.
3. [3] Prager, F., Wei, D., Rose, A., Total economic consequences of an influenza outbreak in the United States. Risk Anal, 2016.
4. [4] Cox N. Pandemic influenza vaccines: lessons learned from the H1N1 influenza pandemic. Presentation at the second WHO consultation on the GAP for influenza vaccines 12–14 July 2011. < http://www.who.int/influenza_vaccines_plan/resources/cox.pdf> [accessed 4 June 2016].
5. [5] Mei, L., Tang, Q., Cui, Y.M., Tobe, R.G., Selotlegeng, L., Ali, A.H., et al. Changes in and shortcomings of drug stockpiling, vaccine development and related policies during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans. Drug Discov Ther 7:3 (2013), 95–100.
6. [6] Options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile. Report from WHO scientific consultation, 1–3 October 2007. < http://www.who.int/csr/resources/publications/WHO_HSE_EPR_GIP_2008_1d.pdf> [accessed 4 June 2016].
7. [7] Berlanda Scorza, F., Tsvetnitsky, V., Donnelly, J.J., Universal influenza vaccines: shifting to better vaccines. Vaccine 34:26 (2016), 2926–2933.
8. [8] de Vries, R.D., Altenburg, A.F., Rimmelzwaan, G.F., Universal influenza vaccines: a realistic option?. Clin Microbiol Infect, 2016.
9. [9] Giersing, B.K., Modjarrad, K., Kaslow, D.C., Moorthy, V.S., Committee WPDfVA, Committee: WPDfVPDA. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015. Vaccine 34:26 (2016), 2865–2869.
10. [10] Hurt, A.C., Kelly, H., Debate regarding oseltamivir use for seasonal and pandemic influenza. Emerg Infect Dis 22:6 (2016), 949–955.
11. [11] Friesen, R.H., Koudstaal, W., Koldijk, M.H., Weverling, G.J., Brakenhoff, J.P., Lenting, P.J., et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE, 5(2), 2010, e9106.
12. [12] Friesen, R.H., Lee, P.S., Stoop, E.J., Hoffman, R.M., Ekiert, D.C., Bhabha, G., et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci USA 111:1 (2014), 445–450.
13. [13] Tharakaraman, K., Subramanian, V., Cain, D., Sasisekharan, V., Sasisekharan, R., Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell Host Microbe 15:5 (2014), 644–651.
14. [14] Ekiert, D.C., Friesen, R.H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333:6044 (2011), 843–850.
15. [15] EU clinical trials register. Clinical trials for eudract_number:2013-002185-39. < https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-002185-39>.
16. [16] Celltrion Website. Press Release: Celltrion announces positive data from phase 1 trial of a novel therapeutic antibody CT-P27. < www.celltrion.com/en/company/notice_view.asp?idx=414&code=ennews&intNowPage=1&menu_num=&align_year=all>.
17. [17] Press Release. FGI successfully completes phase 1A first-in-human clinical trial, 4 November 2011. < http://finance.yahoo.com/news/FGI-Successfully-Completes-iw-2405166867.html>.
18. [18] McAuliffe J, Benjamin E, Wachter L, Palmer-Hill F, Martinez J, Haller L, et al. Pre-clinical studies of a novel monoclonal antibody for treatment of severe influenza A infection. Abstract: Pre-clinical studies of a novel monoclonal antibody for treatment of severe influenza A infection. 4th Influenza research & development conference July 8–10. Boston, USA; 2015.
19. [19] AstraZeneca Website. Press Release: MedImmune receives fast track designation in the US for MEDI8852 for treatment of patients hospitalised with influenza. < https://www.astrazeneca.com/media-centre/press-releases/2016/Medimmune-receives-fast-track-designation-in-the-US-for-MEDI8852-for-treatment-of-patients-hospitalised-with-influenza-A-07032016.html>.
20. [20] Gupta, P., Kamath, A.V., Park, S., Chiu, H., Lutman, J., Maia, M., et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs, 1–7, 2016.
21. [21] Hurt, A.C., Hui, D.S., Hay, A., Hayden, F.G., Overview of the 3rd ISIRV-antiviral group conference – advances in clinical management. Influenza Other Respir Viruses 9:1 (2015), 20–31.
22. [22] Ramos, E.L., Mitcham, J.L., Koller, T.D., Bonavia, A., Usner, D.W., Balaratnam, G., et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 211:7 (2015), 1038–1044.
23. [23] Grandea, A.G. 3rd, Olsen, O.A., Cox, T.C., Renshaw, M., Hammond, P.W., Chan-Hui, P.Y., et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 107:28 (2010), 12658–12663.
24. [24] Presentation Visterra: VIS410, a broadly HA – targeting human antibody, neutralizes H5 and H7 isolates with pandemic potential.
25. [25] Wollacott, A.M., Boni, M.F., Szretter, K.J., Sloan, S.E., Yousofshahi, M., Viswanathan, K., et al. Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine 5 (2016), 147–155.
26. [26] Vistera website. VIS410 for influenza A. < http://www.visterrainc.com/pipeline/vis410.html>.
27. [27] Balasingam, S., Wilder-Smith, A., Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. Int J Infect Dis, 2016.
28. [28] US FDA guidance for industry, influenza: developing drugs for treatment and/or prophylaxis; 2011.
29. [29] Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Heneghan, C.J., Hama, R., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev, 1, 2012, CD008965.
30. [30] Jefferson, T., Jones, M.A., Doshi, P., Del Mar, C.B., Hama, R., Thompson, M.J., et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev(4), 2014, CD008965.
31. [31] WHO statement on public disclosure of clinical trial results. < http://www.who.int/ictrp/results/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1> [accessed 6 June 2016].
32. [32] Chan-Hui, P.Y., Swiderek, K.M., Immunological considerations for developing antibody therapeutics for Influenza A. Hum Vaccin Immunother 12:2 (2016), 474–477.
33. [33] Kelley, B., Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 1:5 (2009), 443–452.
34. [34] MedImmune Website: MEDI8897 receives fast track designation by the FDA for the prevention of respiratory disease caused by RSV in infants. < https://www.medimmune.com/about-us/media/medi8897-receives-fast-track-designation-by-the-fda-for-the-prevention-of-respiratory-disease-caused-by-rsv-in-infants-20150409.html>.